Valuation: Regeneron Pharmaceuticals, Inc.

Capitalization 54.8B 47.72B 44.92B 40.46B 74.91B 4,683B 84.08B 523B 203B 2,144B 206B 201B 7,926B P/E ratio 2025 *
17.5x
P/E ratio 2026 * 14.8x
Enterprise value 45.54B 39.65B 37.33B 33.62B 62.25B 3,891B 69.87B 435B 168B 1,782B 171B 167B 6,587B EV / Sales 2025 *
3.38x
EV / Sales 2026 * 3.07x
Free-Float
77.36%
Yield 2025 *
0.55%
Yield 2026 * 0.58%
More valuation ratios * Estimated data
Dynamic Chart
1 day-0.94%
1 week+6.94%
Current month+5.78%
1 month-1.74%
3 months-27.79%
6 months-32.91%
Current year-27.20%
More quotes
1 week 485
Extreme 485.0001
529.99
1 month 476.49
Extreme 476.4869
617.52
Current year 476.49
Extreme 476.4869
748.29
1 year 476.49
Extreme 476.4869
1,211.2
3 years 476.49
Extreme 476.4869
1,211.2
5 years 441
Extreme 441
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
More quotes
Manager TitleAgeSince
President 65 2000-12-31
Chief Executive Officer 72 1988-01-07
Director of Finance/CFO 54 2024-02-04
Director TitleAgeSince
Chairman 72 2023-06-08
Director/Board Member 84 1991-05-31
Director/Board Member 84 1991-05-31
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-0.94%+6.94%-48.68%-9.31% 54.8B
-0.31%-0.31%+43.99%+62.15% 35.51B
-0.38%+1.60%+65.46%+77.94% 33.43B
+0.23%-0.11%+53.20%-36.74% 26.04B
-1.34%-5.11%+6.74%-26.69% 25.35B
+7.75%+32.96%+58.36%+436.29% 17.85B
-11.32%+0.10%+159.68%+1,943.84% 14.54B
-0.70%+3.20%-21.62%-28.15% 14.08B
+4.13%+11.65%+121.69%-57.23% 13.81B
-2.56%-1.87%+88.06%+128.39% 11.3B
Average -1.47%+4.41%+52.69%+249.05% 24.67B
Weighted average by Cap. -1.12%+4.09%+33.94%+158.02%
See all sector performances

Financials

2025 *2026 *
Net sales 13.47B 11.73B 11.05B 9.95B 18.42B 1,151B 20.67B 129B 49.84B 527B 50.54B 49.49B 1,949B 14.3B 12.45B 11.72B 10.55B 19.54B 1,222B 21.93B 137B 52.87B 559B 53.62B 52.5B 2,068B
Net income 3.17B 2.76B 2.6B 2.34B 4.34B 271B 4.87B 30.3B 11.73B 124B 11.9B 11.65B 459B 3.56B 3.1B 2.92B 2.63B 4.87B 305B 5.47B 34.05B 13.18B 139B 13.37B 13.09B 516B
Net Debt -9.26B -8.06B -7.59B -6.84B -12.66B -791B -14.21B -88.46B -34.25B -362B -34.74B -34.01B -1,340B -10.88B -9.48B -8.92B -8.04B -14.88B -930B -16.7B -104B -40.26B -426B -40.83B -39.98B -1,574B
More financial data * Estimated data
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (53.7%); - revenues from collaboration agreements (42.7%): collaboration with Sanofi (74.8% of revenues), Bayer (24.7%) and other (0.5%); - revenues from sales of technology licenses and subcontracted research services (3.6%). At the end of 2024, the group had a portfolio of approximately 40 products in clinical development.
Employees
15,158
More about the company
Date Price Change Volume
25-06-12 520.48 $ +0.36% 253,409
25-06-11 518.60 $ -0.94% 963,105
25-06-10 523.53 $ +1.15% 1,175,230
25-06-09 517.60 $ +4.94% 1,983,125
25-06-06 493.22 $ +2.10% 1,497,999

Delayed Quote Nasdaq, June 11, 2025 at 04:00 pm EDT

More quotes
Trading Rating
Investor Rating
ESG MSCI
A
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
518.60USD
Average target price
727.21USD
Spread / Average Target
+40.23%
Consensus

Quarterly revenue - Rate of surprise